Medicare AdvantagePrior AuthMedium impact
Inrebic® (fedratinib) (Revised)
Humana·Hematology, Oncology·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has updated prior authorization criteria for Inrebic (fedratinib) for myelofibrosis treatment, effective January 1, 2026. The policy requires patients to have failed or have contraindications to Jakafi (ruxolitinib) before approval and includes strict monitoring requirements due to serious encephalopathy risks.
Action Required
By January 1, 2026: Update prior authorization procedures for Inrebic (fedratinib) prescriptions for Humana Medicare Advantage members. Ensure documentation includes diagnosis of primary or secondary myelofibrosis, risk stratification (intermediate-2 or high-risk), medical reason why Jakafi cannot be used, and confirmation of monotherapy use. Verify thiamine levels are assessed before treatment initiation due to black box warning for encephalopathy.